UNSPSC 51334403: Cinuperone

This classification denotes an anxiolytic and antipsychotic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 072Z5ZP2FI. European Medicines Agency schedules Cinuperone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06318MIG. Cinuperone generally arises in the molecular formula C23H24FN3O.

UNSPSC 51334403 Cinuperone is a Commodity code under which state and local governments procure pharmaceutical products and related health interventions, though recent solicitations under this code show a mismatch between the nominal category name and actual buying activity. The three most recent opportunities solicited naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals with over-the-counter products — reflecting a broader pattern of state health agencies, county health departments, and cooperative purchasing alliances sourcing pharmaceutical inventory, pharmacy benefit program solutions, and controlled-substance management tools. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing vehicles (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving Minnesota and Oregon).

Geographic activity centers on Florida, Texas, and the upper Midwest, with MMCAP's multi-state reach extending procurement across participating jurisdictions including Oregon. Recent representative opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 (posted June 30, 2026, with quarterly deliveries to the Seminole County Community Health Building in Sanford); Texas HHS's RFI on direct-to-manufacturer prescription programs posted April 3, 2026, seeking vendor capabilities for Therapeutic Pharmacy Initiative implementation; and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, requiring vendors to supply through three authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson) with awards effective July 1, 2026. Vendors pursuing this code should expect compliance requirements including FDA certification, cGMP adherence, Drug Supply Chain Security Act compliance, E-Verify authorization, and substantial insurance coverage (commercial general liability of $5 million, professional liability of $2 million in MMCAP's case). No set-aside or disadvantaged-enterprise restrictions appear in the available documentation.